Becton Dickinson and Co (NYSE:BDX) reported fourth-quarter adjusted earnings of $3.96, beating the consensus of$3.92. • BDX is in a challenging position. Follow the breaking news here.The company reported third-quarter 2025 sales of $5.89 billion, slightly below the consensus of$5.90 billion.Revenues increased 8.3% as reported, 7% adjusted FXN, and 3.9% organic.Medical segment sales increased 11.2% (+4% organically) $3.16 billion. Medication Delivery Solutions’ performance reflects strong growth led by Va ...